Immune Rejection Articles & Analysis
6 news found
VX-880 is delivered by an infusion into the hepatic portal vein and requires maintenance immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate -- Caribou ...
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living ...
With typical organ transplants, immuno-suppressive drugs are required to prevent the patient's immune system from rejecting the donated organ. Because the Biostage Esophageal Implant is made using the patient's own cells, Biostage does not expect rejection of the implant. ...
"It seems that mitochondria are immune privileged — we have not seen that they elicit an immune response or any rejection or deterioration of cell functions by transplanting foreign mitochondria," stated Schueller. ...